Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: Results of the randomized NHL13 trial

Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: Results of the randomized NHL13 trial

© 2015 Ferrata Storti Foundation. We investigated rituximab maintenance therapy in patients with diffuse large B-cell lymphoma (n=662) or follicular lymphoma grade 3b (n=21) in first complete remission. Patients were randomized to rituximab maintenance (n=338) or observation (n=345). At a median fol...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ulrich Jaeger, Marek Trneny, Helen Melzer, Michael Praxmarer, Weerasak Nawarawong, Dina Ben Yehuda, David Goldstein, Bilijana Mihaljevic, Osman Ilhan, Veronika Ballova, Michael Hedenus, Liang Tsai Hsiao, Wing Yan Au, Sonja Burgstaller, Gerhard Weidinger, Felix Keil, Christian Dittrich, Cathrin Skrabs, Anton Klingler, Andreas Chott, Michael A. Fridrik, Richard Greil
Format:	Journal
Published:	2018
Subjects:	Agricultural and Biological Sciences
Online Access:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84936160629&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/44919
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	Chiang Mai University

Similar Items

Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: Results of the randomized NHL13 trial
by: Ulrich Jaeger, et al.
Published: (2018)

Optimizing Diagnosis and Treatment Of NHL CD 20+
by: Ami Ashariati Prayoga
Published: (2016)

Glycemic Control of Non-Hodgkin Lymphoma (NHL) Non-Diabetes Mellitus (DM) Patient in the First CHOP Chemotherapy
by: Jualita Heidy Saputri, -, et al.
Published: (2021)

Interstitial pneumonitis : an unusual complication of rituximab
by: Udomsak Bunworasate, et al.
Published: (2008)

Efficacy and safety of rituximab biosimilar in refractory lupus
by: Nantakarn Pongtarakulpanit, et al.
Published: (2020)

Rituximab therapy for treatment of pemphigus in Southeast Asians
by: Silada Kanokrungsee, et al.
Published: (2022)

Current evidence of rituximab in the treatment of multiple sclerosis
by: Techa-angkoon P.
Published: (2023)

INFEKSI TOXOPLASMOSIS, RUBELLA, CYTOMEGALOVIRUS DAN HERPES SIMPLEX VIRUS (TORCH) SEBAGAI FAKTOR RISIKO NEURAL HEARING LOSS (NHL) PADA ANAK
by: , Tumpal Simatupang, et al.
Published: (2014)

Clinical outcome and safety of rituximab therapy for pemphigoid diseases
by: Napatra Tovanabutra, et al.
Published: (2020)

Factors Associated with Complete Remission after Rituximab Therapy for Pemphigus
by: Carolyn J. Kushner, et al.
Published: (2020)

Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients
by: Seree-aphinan C.
Published: (2023)

Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience
by: Lateef, A., et al.
Published: (2016)

The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
by: Marco, H, et al.
Published: (2020)

T Lymphocyte Activation Markers as Predictors of Responsiveness to Rituximab among Patients with FSGS
by: CHAN CHANG YIEN, et al.
Published: (2021)

Rituximab-induced Henoch-Schonlein purpura in a patient with mantle cell lymphoma
by: Watcharoot Kanchongkittiphon, et al.
Published: (2020)

SARS-CoV-2 Humoral Immunity Persists Following Rituximab Therapy
by: Lu, Liangjian, et al.
Published: (2023)

Modulators of rituximab-induced complement-dependent cytotoxicity in diffuse large B-cell lymphoma
by: Ong, Charmaine Zi Yan
Published: (2021)

Rituximab-induced psoriasis in a patient with pemphigus foliaceous: A case report and literature review
by: Norramon Charoenpipatsin, et al.
Published: (2022)

Rituximab as an adjuvant therapy to immune tolerance in a haemophilia A boy with high inhibitor titre
by: Ampaiwan Chuansumrit, et al.
Published: (2018)

Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis
by: Sasimon Borrirukwisitsak, et al.
Published: (2022)

Rituximab-induced psoriasis in a patient with pemphigus foliaceous: A case report and literature review
by: Charoenpipatsin N.
Published: (2023)

Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis
by: Aungsumart S.
Published: (2023)

Radiation Dosimetry in Non-Hodgkin’s B-Cell Lymphoma Patients Treated with 131I-Rituximab Radioimmunotherapy
by: Wirote Changmuang, et al.
Published: (2022)

Refractory Bullous Systemic Lupus Erythematosus Successfully Treated with Rituximab: A Case Report and Literature Review
by: Ratanapokasatit Y.
Published: (2023)

A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center
by: Chiang, J., et al.
Published: (2014)

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
by: Tadeusz Robak, et al.
Published: (2019)

Anti Rituximab antibody titer and therapeutic response in Non-Hodgkin Lymphoma Patient Receiving R-Chop Treatment
by: Roethmia Yaniari, et al.
Published: (2019)

<sup>131</sup>I-rituximab treatment in patient with relapsed non-Hodgkin's lymphoma: The first case report in Thailand
by: Arpakorn Kositwattanarerk, et al.
Published: (2018)

The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate
by: Ampaiwan Chuansumrit, et al.
Published: (2018)

Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab
by: S. Hongeng, et al.
Published: (2018)

Rituximab treatment for paraneoplastic pemphigus associated with follicular B-cell lymphoma: A case report and review of treatment outcome
by: Waranaree Winayanuwattikun, et al.
Published: (2019)

A case of refractory vasculitic ulcers in a systemic lupus erythematosus patient responding to rituximab and hyperbaric oxygen therapy
by: Lui, N.-L., et al.
Published: (2011)

Comparison of the Long-Term Remission of Rituximab and Conventional Treatment for Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Review and Meta-Analysis
by: Weerapat Owattanapanich, et al.
Published: (2020)

Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group
by: Kim, S.J., et al.
Published: (2016)

Low regulatory T-cells: A distinct immunological subgroup in minimal change nephrotic syndrome with early relapse following rituximab therapy
by: CHAN CHANG YIEN, et al.
Published: (2021)

PERAN PEMERINTAH DALAM AKTUALISASI, INTERNALISASI DAN SOSIALISASI NILAI - NILAI PANCASILA
by: , Shely Cathrin
Published: (2011)

Successful treatment of factor x deficiency in a patient with lymphoplasmacytic lymphoma with bendamustine plus rituximab regimen: A case report and literature review
by: Tarinee Rungjirajittranon, et al.
Published: (2022)

Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis
by: Yuanchen Zhao, et al.
Published: (2022)

Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis
by: Zhao Y.
Published: (2023)

QUANTUM COMPUTING AND THE HIDDEN SUBGROUP PROBLEM
by: HERBERT ILHAN TANUJAYA
Published: (2021)